UniQure, Syndax, Erasca Drawing Fresh Analyst Interest
Three clinical-stage biotechs—UniQure, Syndax, and Erasca—are catching analyst attention ahead of key catalysts, with...
Explore Visa cards that provide rewards without the burden of annual fees. Enjoy benefits while saving money.
22,257 articlesThree clinical-stage biotechs—UniQure, Syndax, and Erasca—are catching analyst attention ahead of key catalysts, with...
Oil volatility could create a rare buy-on-dip window for memory names. Jim Cramer says Western Digital and Micron may...
Decades of secrecy around cutting-edge defense programs are giving way to public scrutiny and market reassessment. In...
Two tobacco giants show divergent paths over 10 years, with dividend income boosting returns for both. Here's what ha...
As crypto markets shift, only these crypto tokens sit closest to their all-time highs, signaling selective strength e...
TD Cowen raises its Strategy price target to 395, driven by a shift toward STRC issuance and an improved BTC yield ou...
A rare signal has emerged as markets hit new highs. This article explains what a stock market flashing warning could ...
Bitcoin trades around $81k as the Senate vote on crypto market rules nears. Analysts warn the outcome could spark a r...
Over a five-year span ending May 2026, SPHQ beat JQUA by about 5 percentage points despite a sharper pullback in 2022...
A Kansas City real estate brokerage posts 110% growth from 2021 to 2025, backed by strategic expansion and analytics-...
Investors watch a sharpened geopolitical debate over rare earths as China tightens grip on key materials and the US a...
A retail investor grew a modest $70,000 stake into more than $4 million by mid-2026 using a triple-leveraged S&P 500 ...